HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Publisher： Bentham Science Publishers

E-ISSN： 2212-389x|6|2|228-233

ISSN： 1574-3624

Source： Current Signal Transduction Therapy, Vol.6, Iss.2, 2011-05, pp. : 228-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 83-94

Karger

Access to resources Recommend Favorite

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 7-13

Karger

Access to resources Recommend Favorite

EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Report of a 3-Year Compassionate Use Experience with Gefitinib in Stage IIIB/IV Outpatients

By  

Oncology Research and Treatment, Vol. 28, Iss. 12, 2005-12 ,pp. : 623-627

Karger

Access to resources Recommend Favorite

Developing biomarkers to predict benefit from HGF/MET pathway inhibitors

By  

THE JOURNAL OF PATHOLOGY, Vol. 232, Iss. 2, 2014-01 ,pp. : 210-218

John Wiley & Sons Inc

Access to resources Recommend Favorite